Review: evidence is insufficient to determine the risk–benefit ratio for vision acuity screening in older adults by Quinn, Terry
  
 
 
 
 
Quinn, T. (2016) Review: evidence is insufficient to determine the risk–benefit 
ratio for vision acuity screening in older adults. Annals of Internal Medicine, 
164(12), JC64.  
 
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
 
 
http://eprints.gla.ac.uk/120995/ 
     
 
 
 
 
 
 
Deposited on: 13 July 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Expert commentary on: Chou R, Dana T, Bougatsos C, Grusing S, Blazina I. Screening for impaired 
visual acuity in older adults: updated evidence report and systematic review for the US Preventive 
Services Task Force. JAMA. 2016;315:915-33. 
Commentary 
The ambitious review by Chou and colleagues assesses a screening–treatment-outcome pathway 
and gives a counterintuitive result: Screening detects more vision problems than usual care (27% vs 
3% in 1 study), early treatment is effective, but there is no evidence that screening benefits older 
adults. 
This apparent disconnect may simply relate to sample size. Most healthy older adults do not have 
untreated vision problems, and available treatments are only modestly effective. Thus, 
demonstrating benefit would require larger populations than have been studied. 
The review focused on refractive error, cataracts, and macular degeneration, which are the most 
common—but not the only— causes of disabling vision problems in older adults. 
Heterogeneity in vision problems may explain why screening questions seemed to have poor 
accuracy. Screening questions try to capture all vision problems, whereas the comparator screening 
test (Snellen chart) is specific to vision acuity. 
Useful interventions are not always direct treatments. If screening detects a progressive vision 
problem and the patient is referred to a low-vision service, has home adaptations, and makes an 
informed decision to stop driving, screening, has, arguably, been successful. However, available 
studies using such hard clinical endpoints as vision acuity at follow-up were not designed to assess 
patient outcomes with this level of granularity. 
To interpret this review, clinical context is important. It focused on asymptomatic older adults in 
primary care settings. We should avoid extrapolating the results to vision screening of frail elderly 
persons or comprehensive geriatric assessment. In those settings, the prevalence of potentially 
disabling vision symptoms will be higher and screening will more likely show benefit. 
The review conclusion of “insufficient evidence” for screening is reasonable. It recognizes that better 
evidence for clinical and economic effects is needed before vision screening becomes part of a 
routine older adult health-check. The conclusion does not preclude active case-finding in high-risk 
populations nor comprehensive assessment of older adults presenting with vision symptoms. 
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